CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Oncology Nursing News
Precision Medicine in Oncology
Special Reports in Personalized Cancer Care
SELECT A TOPIC
Attend An Event
State of the Science Summit
Regional Seminar Series
OS by PS in Metastatic Pancreatic Cancer Treatment- Data From an Exploratory Subgroup Analysis
<< View More Conferences
2015 World Conference on Lung Cancer
Oncology Conference Multimedia
View more videos >>
Dr. Bauml on a New Platform to Enhance Lung Cancer Clinical Trial Enrollment
Dr. Pelosof on the Increasing Incidence of Never Smokers in NSCLC
Dr. JÃ¤nne on Biomarker Results From a Study of AZD9291
Oncology Conference Articles
Osimertinib Produces High Response Rate in EGFR T790M-Mutant NSCLC
The third-generation TKI osimertinib (AZD9291) showed a 71% objective response rate in patients with EGFR T790M-mutant nonâ€“small cell lung cancer following resistance to frontline anti-EGFR therapy.
Deep Sequencing Reveals Possible Primary Resistance Mechanism in EGFR-Mutant NSCLC
Coexisting driver mutations in EGFR-mutant nonâ€“small cell lung cancer could potentially contribute to primary resistance to EGFR-targeted therapy.
Cetuximab Improves Survival in EGFR-Positive Squamous NSCLC
The addition of cetuximab (Erbitux) to chemotherapy reduced the risk of death by 44% for patients with advanced squamous nonâ€“small cell lung cancer whose tumors test positive for EGFR gene amplification.
Survival Not Improved by Adjuvant Bevacizumab in NSCLC
The addition of bevacizumab (Avastin) to adjuvant chemotherapy did not improve overall survival in patients with surgically resected early-stage nonâ€“small cell lung cancer.
Survival Trends Higher With Necitumumab in EGFR FISH-Positive Squamous NSCLC
Survival for patients with metastatic squamous nonâ€“small cell lung cancer whose tumors were positive for EGFR copy number as determined by FISH analysis tended to be better when the EGFR antibody necitumumab was added to their conventional chemotherapy.
Potential Role Revealed for EGFR Inhibition Beyond Progression in NSCLC
Continued treatment with gefitinib beyond progression exhibited a trend toward better outcomes in patients with T790M-negative nonÂâ€“small cell lung cancer.
Nivolumab/Ipilimumab Combination Active in Advanced NSCLC
A chemotherapy-free regimen of nivolumab and ipilimumab demonstrated activity as a first-line therapy for patients with advanced nonâ€“small cell lung cancer.
Nivolumab Survival Benefit Sustained in Squamous NSCLC
Treatment with the PD-1 inhibitor nivolumab demonstrated a 32% reduction in the risk of death compared with docetaxel for patients with previously treated squamous nonâ€“small cell lung cancer.
Actionable Mutations Common in Young Lung Cancer Patients
Most patients younger than age 40 with lung cancer had tumors with mutations that can be targeted with existing therapies.
Bevacizumab Triplet Improves Survival in Mesothelioma
Adding bevacizumab (Avastin) to a standard chemotherapy doublet reduced the risk of death by 24% and disease progression by 39% in patients with malignant pleural mesothelioma.
Atezolizumab Plus Chemo Leads to High Response Rate in NSCLC
Patients with newly diagnosed metastatic non-small lung cancer had double the expected response when the PD-L1 inhibitor atezolizumab was added to chemotherapy.
Overregulation May Delay Access to Life-Prolonging Medications, Increase Costs
Overregulation of new drug development has driven up the cost of care and resulted in significant loss of human life by delaying the approval of effective medications.
FDA Approval in HCC, Breakthrough Designation in MCL, and More
Antiangiogenics, ADCs Still Have Roles in Ovarian Cancer Treatment
Triplet Regimen Shows Durable Responses in BRAF V600E-Mutant Metastatic CRC
SM-88 Achieves Encouraging Clinical Benefit Rate in Metastatic Pancreatic Cancer
Novel Strategies Emerging in Uterine Sarcomas
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.